Dr Reddys Laboratories (RDY) Liabilities and Shareholders Equity (2009 - 2026)

Dr Reddys Laboratories has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $6.1 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed 0.1% year-over-year to $6.1 billion in Q2 2026; TTM through Jun 2026 was $24.9 billion, a 8.36% increase from a year earlier, with the FY2026 full-year figure at $6.6 billion, up 13.72% from the prior year.
• Liabilities and Shareholders Equity was $6.1 billion for Q2 2026 at Dr Reddys Laboratories, down from $6.3 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $6.3 billion in Q1 2026, with the low at $3.6 billion in Q3 2022.
• Average Liabilities and Shareholders Equity over 5 years is $5.0 billion, with a median of $4.8 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity slipped 2.9% in 2022, then jumped 32.52% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $3.8 billion in 2022, then advanced by 18.86% to $4.5 billion in 2023, then rose by 27.24% to $5.7 billion in 2024, then climbed by 10.94% to $6.3 billion in 2025, then decreased by 3.86% to $6.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $6.1 billion (Q2 2026), $6.3 billion (Q1 2026), and $6.3 billion (Q4 2025), per Business Quant data.